GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (STU:4LN2) » Definitions » EV-to-FCF

Capricor Therapeutics (STU:4LN2) EV-to-FCF : -12.41 (As of Mar. 27, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Capricor Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Capricor Therapeutics's Enterprise Value is €479.65 Mil. Capricor Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-38.64 Mil. Therefore, Capricor Therapeutics's EV-to-FCF for today is -12.41.

The historical rank and industry rank for Capricor Therapeutics's EV-to-FCF or its related term are showing as below:

STU:4LN2' s EV-to-FCF Range Over the Past 10 Years
Min: -16.63   Med: -3.23   Max: 53.44
Current: -12.46

During the past 13 years, the highest EV-to-FCF of Capricor Therapeutics was 53.44. The lowest was -16.63. And the median was -3.23.

STU:4LN2's EV-to-FCF is ranked worse than
100% of 428 companies
in the Biotechnology industry
Industry Median: 2.855 vs STU:4LN2: -12.46

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-27), Capricor Therapeutics's stock price is €12.02. Capricor Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-1.105. Therefore, Capricor Therapeutics's PE Ratio (TTM) for today is At Loss.


Capricor Therapeutics EV-to-FCF Historical Data

The historical data trend for Capricor Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics EV-to-FCF Chart

Capricor Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.61 -2.16 37.62 -4.16 -11.53

Capricor Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.16 -5.30 -3.47 -13.83 -11.53

Competitive Comparison of Capricor Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Capricor Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Capricor Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's EV-to-FCF falls into.


;
;

Capricor Therapeutics EV-to-FCF Calculation

Capricor Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=479.646/-38.643
=-12.41

Capricor Therapeutics's current Enterprise Value is €479.65 Mil.
Capricor Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-38.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Capricor Therapeutics  (STU:4LN2) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Capricor Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=12.02/-1.105
=At Loss

Capricor Therapeutics's share price for today is €12.02.
Capricor Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.105.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Capricor Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Capricor Therapeutics Business Description

Traded in Other Exchanges
Address
10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.

Capricor Therapeutics Headlines

No Headlines